Best Price Hair Loss Treatment 99% Setipiprant CAS 866460-33-5 Act-129968 Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: TGY2022050507
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: >99%
• Purity: >99%
• Product Name: Setipiprant
• Other Name: Setipiprant Powder
• Appearance: White Crystal
• MW: 402.42
• Certificate: ISO 9001, USP
• Shelf Life: 24 Months
• Storage: Cool Dry Area
• Grade: Pharmaceutical Grade
• CAS No.: 866460-33-5
• Sample: Avaliable
• Service: OEM
• MOQ: 1kg
• Assay: 99%Min, 99% HPLC
• Test Method: UV/HPLC
• Einecs No.: /
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China (Mainland)
• Production Capacity: 300kg/Month

Product Description

Product Name:Setipiprant
Brand Name: ACT129968
CAS No.:866460-33-5
Molecular formula:C24H19FN2O3
Molecular weight: 402.42g/mol
Specification:Pharmaceutical Grade 99%
Appearance: Off-White Powder
Properties: Anti-Hair Loss,Baldness
Shelf Life :2 years
Storage:Room temperature, keep dry and away from light.

Setipiprant (INN) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.

A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.
1. Increase cellular proliferation of outer root sheeth cells.
2. Increase hair diameter and hair density.
3. Increase the percentage of hair in the anagen phase.
4. Exert no negative effect on body hormone levels.
5. Provide equivalent or better net growth than Finasteride.